A detailed history of Larson Financial Group LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 55 shares of NUVL stock, worth $5,307. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55
Previous 29 89.66%
Holding current value
$5,307
Previous $2,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$72.16 - $86.48 $1,876 - $2,248
26 Added 89.66%
55 $4,000
Q2 2025

Aug 08, 2025

BUY
$59.32 - $79.68 $1,720 - $2,310
29 New
29 $2,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.15B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.